Welcome to our dedicated page for Hinge Health SEC filings (Ticker: HNGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Hinge Health, Inc. (NYSE: HNGE) SEC filings, giving investors and researchers a primary source for the company’s regulatory disclosures. As a public company in the healthcare and health information services space, Hinge Health uses its filings to report financial results, describe material events, and document key corporate actions.
Current and prospective shareholders can review periodic reports and current reports on Form 8-K that summarize important developments. Recent 8-K filings have covered topics such as quarterly financial results, the use of non-GAAP financial measures, and the authorization of a share repurchase program for the company’s Class A common stock. These filings often reference accompanying press releases that provide detailed financial statements, reconciliations of non-GAAP metrics, and information about earnings conference calls.
Other 8-K disclosures describe events related to the company’s initial public offering, including lock-up agreements that restrict the sale or transfer of shares for a defined period and the conditions under which certain shares become eligible for earlier release. Such filings help investors understand share supply dynamics, insider selling restrictions, and the timing of potential changes in the public float.
Through its SEC reports, Hinge Health also explains how it presents metrics like calculated billings and discusses the seasonality associated with client launches and platform access. These documents complement the company’s press releases about its AI-powered musculoskeletal care platform, wearable devices, and clinician-supported programs by providing audited or reviewed financial data and formal regulatory context.
On Stock Titan, SEC filings for HNGE are updated as they are posted to the EDGAR system. AI-powered tools can help summarize lengthy documents, highlight key figures, and surface important sections, such as discussions of results of operations, share repurchase details, and other material events disclosed in Hinge Health’s filings.
Hinge Health, Inc. (HNGE)
After this transaction, the director beneficially owns 27,750 shares of Hinge Health Class A common stock directly. No derivative securities transactions were reported in this filing.
HNGE insider Kristina Leslie has filed a Form 144 notice covering the proposed sale of 1,250 shares of HNGE common stock through Morgan Stanley Smith Barney LLC on the NYSE. The shares are valued at an aggregate market value of $57,106.00 based on the filing and are part of a class with 37,919,155 shares outstanding.
The filing shows these shares were acquired as restricted stock from the issuer, with 688 shares acquired on 04/01/2025 and 562 shares on 01/01/2025. Over the prior three months, Leslie reported additional open-market sales of HNGE common stock, including 3,813 shares sold on 11/19/2025 for gross proceeds of $166,257.86 and 2,187 shares sold on 11/18/2025 for $88,476.40.
HNGE filed a notice that an affiliated holder plans to sell common stock under Rule 144. The filing covers 15,000 shares of common stock with an aggregate market value of $680,400.00, to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on the NYSE. The filing notes that there were 37,919,155 shares or other units outstanding at the time of the notice.
The shares to be sold were acquired as performance stock units from the issuer on 04/01/2023, with 15,000 securities acquired on that date and the payment nature listed as "N/A." The seller represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
Hinge Health, Inc. (HNGE) reported an insider stock sale by its Chief Financial Officer. On 11/20/2025, the CFO sold 781 shares of Class A common stock at a price of $44.78 per share in an open-market transaction coded as a sale. This transaction was made under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2025, which is designed to help insiders systematically sell shares over time. Following this sale, the CFO beneficially owns 524,467 shares of Hinge Health common stock in direct ownership.
Hinge Health, Inc. insider Bessemer entities reported major share moves. On November 18, 2025, Bessemer Venture Partners X L.P. and Bessemer Venture Partners X Institutional L.P. converted a total of 4,108,707 shares of Class B Common Stock into 4,108,707 shares of Class A Common Stock under terms described in the company’s charter. On the same date, they sold 725,000 shares of Class A Common Stock at a price of $40.05 per share.
After these transactions, the Bessemer funds reported indirect beneficial ownership of 3,383,707 shares of Class A Common Stock, consisting of 1,745,316 shares held by BVP X and 1,638,391 shares held by BVP X Inst. The reporting entities are described as director-level affiliates and 10% owners of Hinge Health, reflecting significant ongoing ownership even after the sale.
Hinge Health, Inc. (HNGE)November 18, 2025, Bessemer Venture Partners X L.P. converted 2,119,271 shares of Class B Common Stock into 2,119,271 shares of Class A Common Stock, and Bessemer Venture Partners X Institutional L.P. converted 1,989,436 Class B shares into 1,989,436 Class A shares.
On the same date, BVP X sold 373,955 shares of Hinge Health Class A Common Stock and BVP X Institutional sold 351,045 Class A shares. The reporting person, a partner at Bessemer Venture Partners, notes only an indirect, passive economic interest in these Bessemer funds and expressly disclaims beneficial ownership beyond any pecuniary interest.
HNGE filed a Form 144 notice for the proposed public sale of 45,370 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE. The filing lists an aggregate market value of $2,000,817.00 for these shares and states that 37,919,155 shares of the same class are outstanding. The seller acquired 781 shares on 11/15/2025 under an employee stock purchase plan and 44,589 shares on 06/01/2025 from restricted stock units, both from the issuer. By signing, the selling holder represents they are not aware of undisclosed material adverse information about HNGE.
Hinge Health, Inc. (HNGE) reported that one of its directors sold Class A common stock in two transactions. On 11/18/2025, the director sold 2,187 shares at an average price of $40.4556, leaving 32,813 shares beneficially owned. On 11/19/2025, the director sold an additional 3,813 shares at a weighted average price of $43.603, with a remaining holding of 29,000 shares, all held directly.
The company notes that the weighted average price on 11/19/2025 reflects individual sale prices between $43.51 and $43.73, and undertakes to provide detailed breakdowns of the shares sold at each price upon request.
Hinge Health, Inc. (HNGE) reported an insider equity transaction by its President on a Form 4. On 11/18/2025, the officer had 15,977 shares of Class A common stock withheld and cancelled at a price of $40.84 per share to cover federal and state tax obligations arising from the vesting of restricted stock units, in an exempt transaction under Section 16b-3(e). After this tax-withholding event, the officer beneficially owned 804,904 shares of Class A common stock, which include 781 shares acquired on November 14, 2025 through the company’s employee stock purchase plan.
Hinge Health, Inc. (HNGE) reported an insider equity transaction by its Chief Financial Officer on 11/18/2025. The filing shows that 34,903 shares of Class A common stock were disposed of at $40.84 per share in a transaction classified as exempt under Section 16b-3(e). These shares were withheld and cancelled to cover federal and state tax obligations arising from the vesting of restricted stock units, rather than being sold in the open market.
After this tax-withholding event, the CFO beneficially owns 525,248 shares of Class A common stock. This total includes 781 shares acquired on November 14, 2025 through the company’s employee stock purchase plan.